Table 5.

HBsAg prevalence derived from studies among general migrant populations resident in Europe compared to in-country prevalence estimates derived from worldwide systematic reviews

Country	Migrants				In-country of origin			Comparison
	N tested	Prevalence	95% CI	Reference	Prevalence	95% CI	Reference
Afghanistan	293	2.1	0.8–4.4	[30]	10.5	5.9–15.1	[20]	Lower
Albania	504a	11.7	9.0–14.8	[31]	9.0	8.1–9.8	[9]	Higher
Bangladesh	934	1.3	0.7–2.2	[32, 33]	4.8	4.0–5.6	[20]	Lower
Chinab	1319	9.4	7.9–11.1	[33, 34]	10.2 c	9.4–11.2	[20]	Comparable
Dutch Antilles	38	2.6	0.1–13.8	[35]	4.5d	2.5–6.6	[20]	Comparable
Egypt	465	1.1	0.4–2.5	[36]	4.2 c	1.9–6.5	[20]	Lower
Former USSR	675	4.7	3.3–6.6	[30, 37]	3.8	2.7–4.9	[20]	Comparable
India	1334	0.1	0–0.4	[32, 38]	3.2	2.9–3.6	[20]	Lower
Iran	153	0.7	0.1–2.5	[30]	3.1	2.7–3.5	[20]	Lower
Iraq	290	0.7	0–3.6	[30]	1.3	0–2.9	[20]	Comparable
Morocco	305	0.3	0–1.8	[35, 39]	1.8	1.5–5.9	[20, 22]	Lower
Pakistan	3786	1.6	1.2–2.1	[32, 33, 38, 40]	4.2	3.6–4.8	[20]	Lower
Somalia	317	7.3	4.6–10.7	[41]	12.4	8.9–15.9	[20]	Lower
Suriname	56	0	0–6.4	[35]	4.5d	2.5–6.6	[20]	Lower
Turkey	902	3.7	2.5–5.1	[30, 35, 39]	4.3c	3.7–4.9	[20]	Comparable
Vietnam	149	10.7	6.3–16.9	[30, 33]	12.5	11.5–13.5	[20]	Lower

Notes:

^aage range of participants 10–23 years

^bincluding Hong Kong

^cstatistically significant decline over time reported therefore the latest estimate (from year 2000 onwards) selected

^dregional estimate for Caribbean only